Bioaxia Life Sciences Fund LP
Raised
Pre-open
Investors
—
Min Invest
$500,000
AltStreet Analysis
·Generated from EDGAR primary sources
Bioaxia Life Sciences Fund LP is a Delaware-domiciled pooled investment fund filing under Rule 506(b) and Section 3(c), managed by Bioaxia Life Sciences Fund GP LLC and Bioaxia LLC with Douglas Eby as an executive officer. The filing is pre-open with no capital raised or investor count disclosed. The minimum investment is $500,000.
This is a private life sciences fund utilizing the standard 506(b) / 3(c) exemption structure typical of institutional alternative investment vehicles. The $500K minimum investment positions it at the lower end of institutional or high-net-worth qualified purchaser funds, accessible to accredited investors rather than exclusively institutional capital.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Sep 15, 2025
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Latest event New filer · Sep 15, 2025
SEC.govInvestor
- 1 filing event with values and deltas, latest 2025-09-15, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
n/a Bioaxia Life Sciences Fund GP LLC
Executive Officer, Promoter · New York, NY
n/a Bioaxia LLC
Executive Officer, Promoter · New York, NY
Douglas Eby
Executive Officer · New York, NY
Questions About Bioaxia Life Sciences Fund LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Bioaxia Life Sciences Fund LP?
Bioaxia Life Sciences Fund LP is a Delaware limited partnership that filed a Form D with the SEC on September 15, 2025 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is Bioaxia Life Sciences Fund LP legit?
AltStreet does not rate legitimacy; it reports the public record. Bioaxia Life Sciences Fund LP filed a Form D with the SEC on September 15, 2025 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Bioaxia Life Sciences Fund LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Bioaxia Life Sciences Fund LP claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Bioaxia Life Sciences Fund LP raised?
Bioaxia Life Sciences Fund LP reported that the first sale had not yet occurred as of the Form D filed September 15, 2025, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.
Who can invest in Bioaxia Life Sciences Fund LP?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $500,000.
What is the minimum investment in Bioaxia Life Sciences Fund LP?
The Form D lists $500,000 as the minimum investment accepted from any outside investor as of September 15, 2025. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Bioaxia Life Sciences Fund LP and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Bioaxia Life Sciences Fund LP?
The Form D lists 3 related persons: Bioaxia Life Sciences Fund GP LLC, executive officer, promoter (General Partner of the Issuer); Bioaxia LLC, executive officer, promoter (Investment Manager of the Issuer); Douglas Eby, executive officer (Managing Member of the General Partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Bioaxia Life Sciences Fund LP located?
The issuer's address on its SEC filings is 455 10th Avenue, Ph2g, New York, NY 10018. Its phone number of record is 617-999-5008. It is organized under the laws of Delaware.
How long is the Bioaxia Life Sciences Fund LP offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Bioaxia Life Sciences Fund LP?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.